Oramed Pharmaceuticals financials
$4.69−1.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Aug 31 | FY19 Aug 31 | FY18 Aug 31 | FY17 Aug 31 | FY16 Aug 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0.00 | $1.3M | $2.7M | $3.6M | $2.7M | $2.7M | $2.4M | $2.5M | $641.0K |
| Gross profit | $13.0K | $0.00 | $1.3M | $2.7M | $3.6M | $2.7M | $2.6M | $2.5M | $2.3M | $151.0K |
| Gross margin | 0.7% | — | 100.0% | 100.0% | 100.0% | 100.0% | 96.7% | 103.5% | 92.4% | 23.6% |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$36.5M | -$11.8M | -$14.6M | -$13.5M | -$10.8M | -$10.0M |
| Net income | $63.2M | -$19.1M | $5.5M | -$36.6M | -$33.9M | -$11.5M | -$14.4M | -$12.7M | -$10.5M | -$11.0M |
| Net margin | 3162.1% | — | 412.3% | −1352.6% | −940.0% | −424.8% | −531.1% | −519.7% | −426.7% | −1710.5% |
| Diluted EPS | $1.50 | $-0.48 | $0.14 | $-0.94 | $-0.91 | $-0.56 | $-0.82 | $-0.86 | $-0.79 | $-0.87 |
| EBITDA | -$15.0M | -$12.6M | -$15.6M | -$40.5M | -$36.5M | -$11.8M | -$14.6M | -$13.5M | -$10.8M | -$10.0M |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$32.3M | -$12.4M | -$12.9M | -$14.7M | -$5.8M | $4.7M |
| Free cash flow | -$74.1M | -$9.7M | -$10.5M | -$28.4M | -$32.7M | -$12.5M | -$13.0M | -$14.7M | -$5.8M | $4.6M |
| Diluted shares | 42.4M | 40.9M | 40.6M | 39.0M | 37.1M | 20.5M | 17.5M | 14.9M | 13.3M | 12.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Aug 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.9M | $54.4M | $9.1M | $40.5M | $27.5M | $19.3M |
| Short-term investments | $69.0M | $32.2M | $57.7M | $3.7M | $7.7M | $9.5M |
| Total debt | $0.00 | $329.0K | $51.3M | $1.0K | $0.00 | $0.00 |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $177.8M | $44.6M |
| Total liabilities | $31.1M | $9.9M | $57.7M | $10.5M | $11.2M | $11.8M |
| Shareholders' equity | $199.7M | $145.3M | $162.9M | $151.2M | $166.6M | $32.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology